Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06765668 · ClinicalTrials.gov registry record · Phase 4

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

A Phase 4 study of Parkinson Disease, sponsored by Impax Laboratories.

Recruiting
Registry status
Phase 4
Development phase
220
Enrollment target
20
Study locations

NCT06765668 is a Phase 4 study of Parkinson Disease that is actively recruiting participants, run by Impax Laboratories. The registered enrollment target is 220 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06765668, a Phase 4 study of Parkinson Disease, is actively recruiting participants, sponsored by Impax Laboratories.

RECRUITING
Registry status
Phase 4
Development phase
220 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

Conditions Studied

Parkinson Disease

Interventions

  • DRUG CREXONT ER

Study Locations (20)

Florida

  • Visionary Investigators Network - Aventura
  • Parkinsons Disease and Movement Disorders Center of Boca Raton - Boca Raton
  • Univesity of Miami - Miller School of Medicine - Boca Raton
  • University of Miami - Miami
  • N1 Research LLC - Orlando
  • USF Parkinson's Disease and Movement Disorders Center - Tampa

Ohio

  • NeuroScience Research Center, LLC - Canton
  • University of Cincinnati - Cincinnati
  • University Hospitals Cleveland Medical Center - Cleveland

California

  • Parkinson's Research Centers of America - Orange County - Aliso Viejo
  • Parkinson's Research Centers of America - Palo Alto - Palo Alto

Arizona

  • Barrow Neurological Institute - Phoenix

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Illinois

  • Central DuPage Hospital - Movement Disorders Center - Winfield

Kansas

  • University of Kansas Medical Center - Kansas City

Michigan

  • Quest Research Institute - Farmington Hills

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2025-02-12
Est. Completion 2026-08-06
Phase Phase 4

Sponsor

Impax Laboratories

19 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06765668

The ClinicalTrials.gov registry entry for NCT06765668 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which CREXONT ER is the first listed.

NCT06765668 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT06765668 about?

NCT06765668 is a clinical study titled "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease". The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

What is the current status of trial NCT06765668?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2025-02-12. Estimated completion is 2026-08-06.

What conditions does trial NCT06765668 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT06765668?

The interventions under investigation include: CREXONT ER (DRUG).

Who is sponsoring clinical trial NCT06765668?

This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06765668 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.